Form 4 for HIND Vyome Holdings, Inc

Accepted 2021-09-17 00:00:00 ET · period of report 2021-07-22 · accession 0001790300-21-000011 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2021-09-17	2021-07-22	HIND	Bandy Barton P.	Pres, CEO, Dir	A - Grant	$0.00	+1.19M	1.19M	New	$0
	2021-09-17	2021-09-10	HIND	Bandy Barton P.	Pres, CEO, Dir	S - Sale	$2.89	-294.5K	891.5K	-25%	-$851.1K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, $0.001 par value per share	2021-07-22	A	A	960,100	$0.00	960,100	D	—	—	(F1) These shares will vest and be issued with respect to 480,050 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
2	Common	Common Stock, $0.001 par value per share	2021-09-10	S	D	294,494	$2.89	891,512	D	—	—	(F4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
3	Common	Common Stock, $0.001 par value per share	2021-07-22	A	A	225,906	$0.00	1,186,006	D	—	—	(F2) These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.